HBV研究模型新进展

doi:10.3969/j.issn.1004-616x.2019.02.014

癌变·畸变·突变 ›› 2019, Vol. 31 ›› Issue (2): 166-170.doi: 10.3969/j.issn.1004-616x.2019.02.014

• 综述 • 上一篇

HBV研究模型新进展

毕延伟^1,2,3, 杨小强^1,2,3, 孙平楠^1,2,3, 周小玲^1,2,3

1. 汕头大学医学院干细胞P2实验室, 广东汕头 515041;
2. 汕头大学医学院生殖医学中心, 广东汕头 515041;
3. 广东省感染病与分子免疫病理重点实验室, 广东汕头 515041

收稿日期:2018-06-26 修回日期:2019-03-11 出版日期:2019-03-30 发布日期:2019-03-30
通讯作者: 周小玲,E-mail:xlzhou@stu.edu.cn E-mail:xlzhou@stu.edu.cn
作者简介:毕延伟,E-mail:726346953@qq.com;杨小强,E-mail:498360635@qq.com
基金资助:
国家自然基金（81570567，81571994，81870432）；广东省自然科学基金（2014A030313483，2015A030313447）

Received:2018-06-26 Revised:2019-03-11 Online:2019-03-30 Published:2019-03-30

摘要/Abstract

摘要： 慢性乙型肝炎病毒（HBV）感染是造成肝炎、肝硬化、肝癌的主要诱因之一，已成为全球性的公共健康问题。乙型肝炎疫苗的推广应用显著降低了HBV感染率，但现阶段慢性乙肝病毒感染仍然无法根治。HBV研究模型对推动HBV相关研究和临床治疗起到了重要的作用。然而，由于缺乏合适的研究模型，HBV生物学以及HBV与宿主之间相互作用等方面仍存在很多问题未明了，制约了抗HBV新药研发。近年来，HBV功能性受体钠离子-牛磺胆酸共转运多肽（NTCP）的发现以及干细胞技术的发展应用，极大推动了HBV研究模型的发展。本文分别从病毒来源、细胞和动物感染模型等角度对HBV研究模型领域的进展进行综述。

关键词: 乙型肝炎病毒, 研究模型, 钠离子-牛磺胆酸共转运多肽, 类肝细胞

中图分类号:

Q933

毕延伟, 杨小强, 孙平楠, 周小玲. HBV研究模型新进展[J]. 癌变·畸变·突变, 2019, 31(2): 166-170.

参考文献

[1] ZHANG Y,ZHANG H,ELIZABETH A,et al. Epidemiology of hepatitis B and associated liver diseases in china[J]. Chin Med Sci J,2013,27(4):243-248.
[2] ZHANG Q,LIAO Y,CHEN J,et al. Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China[J]. Sci Rep,2015,5:17413.
[3] BLANK A,MARKERT C,HOHMANN N,et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B[J]. J Hepatol,2016,65(3):483-489.
[4] SPITZ N,MOREIRA A S,MELLO F C A,et al. Complete genome sequence of a hepatitis B virus isolate of genotype D2,subtype adrq+,from Brazil[J]. Arch Virol,2017,162(6):1695-1700.
[5] SELLS M A,CHEN M L,ACS G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA[J]. Proc Natl Acad Sci U S A,1987,84(4):1005-1009.
[6] LADNER S K,OTTO M J,BARKER C S,et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells:a novel system for screening potential inhibitors of HBV replication[J]. Antimicrob Agents Chemother,1997,41(8):1715-1720.
[7] YING C,DE CLERCQ E,NEYTS J. Selective inhibition of hepatitis B virus replication by RNA interference[J]. Biochem Biophys Res Commun,2003,309(2):482-484.
[8] SEIFER M,HEERMANN K H,GERLICH W H. Replication of hepatitis B virus in transfected nonhepatic cells[J]. Virology,1990,179(1):300-311.
[9] GLEBE D,BERTING A,BROEHL S,et al. Optimised conditions for the production of hepatitis B virus from cell culture[J]. Intervirology,2001,44(6):370-378.
[10] CHANG C M,JENG K S,HU C P,et al. Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line[J]. EMBO J,1987,6(3):675-680.
[11] ALLWEISS L,VOLZ T,GIERSCH K,et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut,2018,67(3):542-552.
[12] ZEISEL M B,LUCIFORA J,MASON W S,et al. Towards an HBV cure:state-of-the-art and unresolved questions——report of the ANRS workshop on HBV cure[J]. Gut,2015,64(8):1314-1326.
[13] CHEN Z J,YE J. Getting to grips with hepatitis[J]. Elife,2012,1:e00301.
[14] YAN H,LIU Y,SUI J,et al. NTCP opens the door for hepatitis B virus infection[J]. Antiviral Res,2015,121:24-30.
[15] GRIPON P,RUMIN S,URBAN S,et al. Infection of a human hepatoma cell line by hepatitis B virus[J]. Proc Natl Acad Sci U S A,2002,99(24):15655-15660.
[16] LEE J,ZONG L,KROTOW A,et al. N-linked glycosylation is not essential for sodium taurocholate cotransporting polypeptide to mediate hepatitis B virus infection in vitro[J]. J Virol,2018,92(15):e00732-18.
[17] JIANG Y,WANG A H,SHAO L H,et al. A new cell culture system for infection with hepatitis B virus that fuses HepG2 cells with primary human hepatocytes[J]. J Int Med Res,2009,37(3):650-661.
[18] YANG D,ZUO C,WANG X,et al. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line[J]. Proc Natl Acad Sci U S A,2014,111(13):1264-1273.
[19] YAN H,ZHONG G,XU G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife,2012,1:e00049.
[20] NI Y,LEMPP F A,MEHRLE S,et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J]. Gastroenterology,2014,146(4):1070-1083.
[21] WATASHI K,URBAN S,LI W,et al. NTCP and beyond:opening the door to unveil hepatitis B virus entry[J]. Int J Mol Sci,2014,15(2):2892-2905.
[22] IWAMOTO M,WATASHI K,TSUKUDA S,et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP[J]. Biochem Biophys Res Commun,2014,443(3):808-813.
[23] SCHULZE A,MILLS K,WEISS T S,et al. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus[J]. Hepatology,2012,55(2):373-383.
[24] OKUYAMA-DOBASHI K,KASAI H,TANAKA T,et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide[J]. Sci Rep,2015,5:17047.
[25] VERRIER E R,COLPITTS C C,BACH C,et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses[J]. Hepatology,2016,63(1):35-48.
[26] MICHAILIDIS E,PABON J,XIANG K,et al. A robust cell culture system supporting the complete life cycle of hepatitis B virus[J]. Sci Rep,2017,7(1):16616.
[27] KO C,LEE S,WINDISCH M P,et al. DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level[J]. J Virol,2014,88(23):13689-13698.
[28] KO C,PARK W J,PARK S,et al. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide[J]. Antivir Ther,2015,20(8):835-842.
[29] URBAN S,BARTENSCHLAGER R,KUBITZ R,et al. Strategies to inhibit entry of HBV and HDV into hepatocytes[J]. Gastroenterology,2014,147(1):48-64.
[30] PAGANELLI M,DALLMEIER K,NYABI O,et al. Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection[J]. Hepatology,2013,57(1):59-69.
[31] XIA Y,CARPENTIER A,CHENG X,et al. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection,spreading and virus-host interactions[J]. J Hepatol,2017,66(3):494-503.
[32] SHLOMAI A,SCHWARTZ R E,RAMANAN V,et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems[J]. Proc Natl Acad Sci U S A,2014,111(33):12193-12198.
[33] SUN P,ZHOU X,FARNWORTH S L,et al. Modeling human liver biology using stem cell-derived hepatocytes[J]. Int J Mol Sci,2013,14(11):22011-22021.
[34] WIELAND S F. The chimpanzee model for hepatitis B virus infection[J]. Cold Spring Harb Perspect Med,2015,5(6):[35] DUPINAY T,GHEIT T,ROQUES P,et al. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island[J]. Hepatology,2013,58(5):1610-1620.
[36] WALTER E,KEIST R,NIEDEROST B,et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo[J]. Hepatology,1996,24(1):1-5.
[37] WU X,XU H,ZHANG Z,et al. Transcriptome profiles using next-generation sequencing reveal liver changes in the early stage of diabetes in Tree Shrew (Tupaia belangeri chinensis)[J]. J Diabetes Res,2016,2016:6238526.
[38] BISSIG K D,WIELAND S F,TRAN P,et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment[J]. J Clin Invest,2010,120(3):924-930.
[39] ISHIDA Y,YAMASAKI C,YANAGI A,et al. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice[J]. Am J Pathol,2015,185(5):1275-1285.
[40] BILITY M T,CHENG L,ZHANG Z,et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model:induction of human-specific liver fibrosis and M2-like macro-phages[J]. PLoS Pathog,2014,10(3):e1004032.
[41] NI Y,URBAN S. Stem cell-derived hepatocytes:A promising novel tool to study hepatitis B virus infection[J]. J Hepatol,2017,66(3):473-475.

HBV研究模型新进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	孙平楠，周小玲，杨少哲，程琳，姚伟城. 人胚胎干细胞来源的肝细胞：一种具有潜力的乙肝病毒研究模型[J]. 癌变·畸变·突变, 2014, 26(5): 339-342.
[2]	贺丹丹,邓志华,杨倩. HBX蛋白对正常肝细胞增殖及端粒酶活性的影响[J]. , 2012, 24(3): 183-187.
[3]	刘冬玲(综述),黄天华*(审校). RNA干扰抑制乙型肝炎病毒研究进展[J]. , 2011, 23(3): 242-.
[4]	张　南訾晓渊熊　俊姚玉成李文林巴　月朱海英李建秀王新民胡以平. 乙肝病毒X蛋白诱导HeLa细胞和转基因小鼠肝细胞凋亡的研究[J]. , 2007, 19(2): 85-088.
[5]	熊小芳;黄天华;谢庆东;王晓梅;陈桂兰. 精子携带的HBV DNA在小鼠早期胚胎中的复制与表达[J]. , 2005, 17(3): 175-178.
[6]	陈桂兰;黄天华;谢庆东;王晓梅;熊小芳. 卵母细胞带的HBV NA在小鼠期胚胎中的制与表达[J]. , 2005, 17(3): 179-182.
[7]	田　甜 ;訾晓渊;综述，胡以平审校. 细胞毒性T淋巴细胞在乙型肝炎发病中的作用[J]. , 2004, 16(2): 114-116.
[8]	张清健　谢庆东　综述，黄天华　审校. 乙型肝炎病毒垂直传播新途径的研究[J]. , 2003, 15(2): 121-123.
[9]	方玲，姚玉成，案宏彪，谢庆东．赵书民，王忠华，余宏宇，胡以平. HBV表面抗原DNA疫苗对小鼠脏器影响的实验研究[J]. , 2000, 12(4): 202-204.
[10]	黄建民1 　黄天华1 　邱焕英2 　邱杰文3 　方小武1 　陈晓红1 　庄天罡1 　蔡树深1 　王永华2 　刘鸿禧1 　杨风霞2 　刘卫东2. 乙型肝炎病毒对精子染色体的影响[J]. , 1999, 11(2): 72-074.